ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Speaking at the Wellcome Trust in London last week, GlaxoSmithKline CEO Andrew Witty announced three initiatives that he says advance the firm’s commitment to openness. The British drug firm has screened its library of 2 million compounds and is making freely available about 200 molecules with signs of activity against tuberculosis. The company will spend about $8 million to double funding at its “open lab” in Tres Cantos, Spain, where independent scientists can research diseases of the developing world. And it will create a system that enables researchers to access detailed, anonymized patient data from clinical trials of its approved and discontinued drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter